Evolving relevance of neuroproteomics in Alzheimer’s disease

Simone Lista, Henrik Zetterberg, Sidney O'Bryant, Kaj Blennow, Harald Hampel

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

5 Citations (Scopus)

Abstract

Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages101-115
Number of pages15
DOIs
StatePublished - 1 Jan 2017

Publication series

NameMethods in Molecular Biology
Volume1598
ISSN (Print)1064-3745

Fingerprint

Alzheimer Disease
Systems Biology
Biomarkers
Early Diagnosis
Mass Spectrometry
Neurodegenerative Diseases
Proteomics
Technology
Sensitivity and Specificity
Peptides
Proteins
Therapeutics

Keywords

  • Alzheimer’s disease
  • Biomarkers
  • Blood
  • Cerebrospinal fluid
  • Detection/diagnosis
  • Mass spectrometry
  • Neuroproteomics
  • Omics sciences
  • Plasma/serum
  • Proteomics
  • Systems biology

Cite this

Lista, S., Zetterberg, H., O'Bryant, S., Blennow, K., & Hampel, H. (2017). Evolving relevance of neuroproteomics in Alzheimer’s disease. In Methods in Molecular Biology (pp. 101-115). (Methods in Molecular Biology; Vol. 1598). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-6952-4_5
Lista, Simone ; Zetterberg, Henrik ; O'Bryant, Sidney ; Blennow, Kaj ; Hampel, Harald. / Evolving relevance of neuroproteomics in Alzheimer’s disease. Methods in Molecular Biology. Humana Press Inc., 2017. pp. 101-115 (Methods in Molecular Biology).
@inbook{0f58a9b509054480a88d589e3fb60b90,
title = "Evolving relevance of neuroproteomics in Alzheimer’s disease",
abstract = "Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.",
keywords = "Alzheimer’s disease, Biomarkers, Blood, Cerebrospinal fluid, Detection/diagnosis, Mass spectrometry, Neuroproteomics, Omics sciences, Plasma/serum, Proteomics, Systems biology",
author = "Simone Lista and Henrik Zetterberg and Sidney O'Bryant and Kaj Blennow and Harald Hampel",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-6952-4_5",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "101--115",
booktitle = "Methods in Molecular Biology",

}

Lista, S, Zetterberg, H, O'Bryant, S, Blennow, K & Hampel, H 2017, Evolving relevance of neuroproteomics in Alzheimer’s disease. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1598, Humana Press Inc., pp. 101-115. https://doi.org/10.1007/978-1-4939-6952-4_5

Evolving relevance of neuroproteomics in Alzheimer’s disease. / Lista, Simone; Zetterberg, Henrik; O'Bryant, Sidney; Blennow, Kaj; Hampel, Harald.

Methods in Molecular Biology. Humana Press Inc., 2017. p. 101-115 (Methods in Molecular Biology; Vol. 1598).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Evolving relevance of neuroproteomics in Alzheimer’s disease

AU - Lista, Simone

AU - Zetterberg, Henrik

AU - O'Bryant, Sidney

AU - Blennow, Kaj

AU - Hampel, Harald

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.

AB - Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.

KW - Alzheimer’s disease

KW - Biomarkers

KW - Blood

KW - Cerebrospinal fluid

KW - Detection/diagnosis

KW - Mass spectrometry

KW - Neuroproteomics

KW - Omics sciences

KW - Plasma/serum

KW - Proteomics

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=85019599153&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-6952-4_5

DO - 10.1007/978-1-4939-6952-4_5

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 101

EP - 115

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

Lista S, Zetterberg H, O'Bryant S, Blennow K, Hampel H. Evolving relevance of neuroproteomics in Alzheimer’s disease. In Methods in Molecular Biology. Humana Press Inc. 2017. p. 101-115. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-6952-4_5